NPI-001

N/A

Report date: 2025/05/29 16:51:00

Base Information

Drug NameNPI-001
Drug Alias NameN-acetylcysteine-amideAD-4NACANPI-001AT-001
ClassificationSmall molecules
Mechanisms of ActionFree radicals scavengersantioxidant
TargetsFree radicals
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Autism Spectrum DisorderFeeding and Eating Disorders +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNacuity Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNacuity Pharmaceuticals IncArctic Therapeutics InternationalThe University Of Queensland +[9] 
Inactive CompaniesOhsu Knight Cancer InstituteUniversity Of MissouriSoroka University Medical Center +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Feeding and Eating DisordersDiabetes Mellitus +[11] 
Inactive IndicationsAutism Spectrum DisorderDrug-Related Side Effects and Adverse ReactionsInflammation +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBank